Floatz logo

Regorafenib

Brain Metastases, Adult

Neonc Technologies, Inc.Small moleculePhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

102 Active assets in the Brain Metastases, Adult cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
Iambic Therapeutics, Inc
Phase 4BB
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BB
Icotinib
Betta Pharmaceuticals Co., Ltd.
Phase 3BB
Trastuzumab Deruxtecan
Baptist Health South Florida
Phase 4BB
Capecitabine
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3BB

View all 50 →

Same molecule, other indications

Regorafenib is also rated in:

gastrointestinal stromal tumorDormant
BBB
Indicative ·
73 / 100
View asset →
colorectal neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
RegorafenibDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →